CAJ | 학술논문

目的：探讨单用培美曲塞或多西他赛二线化疗药物治疗化疗失败的晚期非小细胞肺癌（ NSCLC ）的临床疗效及安全性。方法共纳入60例一线治疗失败的局部晚期NSCLC患者，采用随机数字法平均分为A组、B组。 A组单用培美曲塞化疗，B组单用多西他赛治疗。观察2组患者的近远期临床疗效及不良反应的发生情况。结果 A组、B组总有效率分别为66．67％、63．33％，2组比较，差异无统计学意义（P＞0．05）。A组患者白细胞降低、脱发发生率明显低于B组患者，2组比较差异有统计学意义（P＜0．05）；血小板降低、贫血、恶性呕吐、皮疹等比较差异不明显（P＞0．05）。A组患者6个月、1年生存率分别为46．67％、30．00％，B组6个月、1年生存率分别为40．00％、23．33％，2组比较差异无统计学意义（ P＞0．05）。结论单用培美曲塞或多西他赛治疗化疗失败的晚期NSCLC均有较好的临床疗效，可作为二线化疗药物，但培美曲塞白细胞降低不良反应较多西他赛发生率低。
목적：탐토단용배미곡새혹다서타새이선화료약물치료화료실패적만기비소세포폐암（ NSCLC ）적림상료효급안전성。방법공납입60례일선치료실패적국부만기NSCLC환자，채용수궤수자법평균분위A조、B조。 A조단용배미곡새화료，B조단용다서타새치료。관찰2조환자적근원기림상료효급불량반응적발생정황。결과 A조、B조총유효솔분별위66．67％、63．33％，2조비교，차이무통계학의의（P＞0．05）。A조환자백세포강저、탈발발생솔명현저우B조환자，2조비교차이유통계학의의（P＜0．05）；혈소판강저、빈혈、악성구토、피진등비교차이불명현（P＞0．05）。A조환자6개월、1년생존솔분별위46．67％、30．00％，B조6개월、1년생존솔분별위40．00％、23．33％，2조비교차이무통계학의의（ P＞0．05）。결론단용배미곡새혹다서타새치료화료실패적만기NSCLC균유교호적림상료효，가작위이선화료약물，단배미곡새백세포강저불량반응교다서타새발생솔저。
Objective To study the efficacy and safety of second-line chemotherapy drug for advanced non-small cell lung cancer .Methods 60 patients with advanced non-small cell lung cancer were included .All patients had failed on first-line chemotherapy drugs treatment ,and they were divided into group A and group B .Group A was given pemetrexed alone and group B was given docetaxel alone .The curative effect and the occurrence of adverse reactions were observed .Results The effective rates of group A and group B were 66.67%,63.33%,respectively.The difference was not statistically significant (P>0.05).The rates of leucopenia and alopecia in group A were lower than those of group B ,the differences were statistically significant (P<0.05). Thrombocytopenia,anemia,pernicious vomiting and rash of the 2 groups had no obvious difference (P>0.05).The 6-month,1-year survival rates in group A were 46.67% and 30.00%,respectively.The 6-month,1-year survival rates in group B were 40.00%and 23.33%,respectively.The difference was not statistically significant (P>0.05).Conclusion Single pemetrexed or docetaxel as second-line chemotherapy in the treatment of patients with advanced non-small cell lung cancer are effective ,and both of them can be a choice of second-line chemotherapy in the treatment of patients with advanced non-small cell lung cancer , while pemetrexed has fewer side effects .